Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes

M Gejl; H M Søndergaard; Chalotte Willemann Stecher; Bo Martin Bibby; N Møller; H E Bøtker; S B Hansen; Albert Gjedde; Jørgen Rungby; B Brock

doi:10.1210/jc.2011-3456

Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes

M Gejl, H M Søndergaard, Chalotte Willemann Stecher, Bo Martin Bibby, N Møller, H E Bøtker, S B Hansen, Albert Gjedde, Jørgen Rungby, B Brock

Eyepath Lab

Research output: Contribution to journal › Journal article › Research › peer-review

64 Citations (Scopus)

Abstract

Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists provide beneficial cardiovascular effects by protecting against ischemia and reperfusion injury. Type 2 diabetes mellitus patients have reduced glycolysis in the heart.

Original language	English
Journal	The Journal of clinical endocrinology and metabolism
Volume	97
Issue number	7
Pages (from-to)	E1165-9
Number of pages	5
ISSN	0021-972X
DOIs	https://doi.org/10.1210/jc.2011-3456
Publication status	Published - Jul 2012

Keywords

Biological Transport
Coronary Circulation
Cross-Over Studies
Diabetes Mellitus, Type 2
Double-Blind Method
Glucose
Heart
Humans
Hypoglycemic Agents
Insulin Resistance
Male
Middle Aged
Myocardium
Peptides
Placebos
Positron-Emission Tomography
Regional Blood Flow
Up-Regulation
Venoms

Access to Document

10.1210/jc.2011-3456

Cite this

Gejl, M., Søndergaard, H. M., Stecher, C. W., Bibby, B. M., Møller, N., Bøtker, H. E., Hansen, S. B., Gjedde, A., Rungby, J., & Brock, B. (2012). Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism, 97(7), E1165-9. https://doi.org/10.1210/jc.2011-3456

Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. / Gejl, M; Søndergaard, H M; Stecher, Chalotte Willemann; Bibby, Bo Martin; Møller, N; Bøtker, H E; Hansen, S B; Gjedde, Albert; Rungby, Jørgen; Brock, B.

In: The Journal of clinical endocrinology and metabolism, Vol. 97, No. 7, 07.2012, p. E1165-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Gejl, M, Søndergaard, HM, Stecher, CW, Bibby, BM, Møller, N, Bøtker, HE, Hansen, SB, Gjedde, A, Rungby, J & Brock, B 2012, 'Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes', The Journal of clinical endocrinology and metabolism, vol. 97, no. 7, pp. E1165-9. https://doi.org/10.1210/jc.2011-3456

Gejl, M ; Søndergaard, H M ; Stecher, Chalotte Willemann ; Bibby, Bo Martin ; Møller, N ; Bøtker, H E ; Hansen, S B ; Gjedde, Albert ; Rungby, Jørgen ; Brock, B. / Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. In: The Journal of clinical endocrinology and metabolism. 2012 ; Vol. 97, No. 7. pp. E1165-9.

@article{a7ad41666b55486fa829d82c2358d1d0,

title = "Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes",

abstract = "Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists provide beneficial cardiovascular effects by protecting against ischemia and reperfusion injury. Type 2 diabetes mellitus patients have reduced glycolysis in the heart.",

keywords = "Biological Transport, Coronary Circulation, Cross-Over Studies, Diabetes Mellitus, Type 2, Double-Blind Method, Glucose, Heart, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Myocardium, Peptides, Placebos, Positron-Emission Tomography, Regional Blood Flow, Up-Regulation, Venoms",

author = "M Gejl and S{\o}ndergaard, {H M} and Stecher, {Chalotte Willemann} and Bibby, {Bo Martin} and N M{\o}ller and B{\o}tker, {H E} and Hansen, {S B} and Albert Gjedde and J{\o}rgen Rungby and B Brock",

year = "2012",

month = jul,

doi = "10.1210/jc.2011-3456",

language = "English",

volume = "97",

pages = "E1165--9",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes

AU - Gejl, M

AU - Søndergaard, H M

AU - Stecher, Chalotte Willemann

AU - Bibby, Bo Martin

AU - Møller, N

AU - Bøtker, H E

AU - Hansen, S B

AU - Gjedde, Albert

AU - Rungby, Jørgen

AU - Brock, B

PY - 2012/7

Y1 - 2012/7

N2 - Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists provide beneficial cardiovascular effects by protecting against ischemia and reperfusion injury. Type 2 diabetes mellitus patients have reduced glycolysis in the heart.

AB - Glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists provide beneficial cardiovascular effects by protecting against ischemia and reperfusion injury. Type 2 diabetes mellitus patients have reduced glycolysis in the heart.

KW - Biological Transport

KW - Coronary Circulation

KW - Cross-Over Studies

KW - Diabetes Mellitus, Type 2

KW - Double-Blind Method

KW - Glucose

KW - Heart

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin Resistance

KW - Male

KW - Middle Aged

KW - Myocardium

KW - Peptides

KW - Placebos

KW - Positron-Emission Tomography

KW - Regional Blood Flow

KW - Up-Regulation

KW - Venoms

U2 - 10.1210/jc.2011-3456

DO - 10.1210/jc.2011-3456

M3 - Journal article

C2 - 22544917

VL - 97

SP - E1165-9

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -